Drugs
Abraxis Receives Approval from EU Commission to Market ABRAXANE for Metastatic Breast Cancer in Europe
Published in Cancer Weekly, February 5th, 2008
Abraxis BioScience, Inc. (Abraxis) (NASDAQ:ABII), an integrated biotechnology company, announced that the European Commission has granted marketing approval for ABRAXANE(R) powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel) for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated. The Phase III clinical trial results on which this approval was based demonstrated that ABRAXANE doubled the response rate and significantly prolonged progression-free survival and overall survival versus Taxol(R) in the approved...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-02-05)
More Articles from Cancer Weekly
- Cancer Vaccines
Newly discovered virus linked to deadly skin cancer - Better Health Publishing
Breakthrough Study Links Prostate Cancer, Depression, IBS, Adrenal Fatigue and Allergies to Lead and Mercury Toxic Load in Body - Biophysics
New biophysics study findings recently were reported by J.M. Escoffre and co-researchers - Cancer Gene Therapy
Study data from Sichuan University provide new insights into cancer gene therapy - Cancer Vaccines
Research from A. Pallecarosa et al has provided new information about cancer vaccines - Cancer Vaccines
Research from S.I. Liu and co-researchers yields new findings on cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
